Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell CarcinomaHui Luo, Guangqiang Zhao, Yiping Zhang et al.|JAMA|2021Cited by 821
Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer: an open‐label, randomized controlled phase 3 trial (ORIENT‐3)Yuankai Shi, Luyao Sun, Lin Wu et al.|癌症：英文版|2022Cited by 60
Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)Yuankai Shi, Xiaoyan Kang, Jianhua Chen et al.|BMC Medicine|2023Cited by 24